Vistagen Therapeutics Files 8-K on Financials
Ticker: VTGN · Form: 8-K · Filed: Nov 13, 2025 · CIK: 1411685
| Field | Detail |
|---|---|
| Company | Vistagen Therapeutics, Inc. (VTGN) |
| Form Type | 8-K |
| Filed Date | Nov 13, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-k
Related Tickers: VTGN
TL;DR
VTGN filed an 8-K on Nov 13, 2025, updating financials. Check it out.
AI Summary
Vistagen Therapeutics, Inc. filed an 8-K on November 13, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits related to the period ending November 13, 2025. The company, incorporated in Nevada, is based in South San Francisco, California.
Why It Matters
This 8-K filing provides an update on Vistagen Therapeutics' financial performance and condition, which is crucial for investors to assess the company's stability and future prospects.
Risk Assessment
Risk Level: low — This filing is a routine 8-K reporting financial information and does not appear to contain any immediate material adverse events.
Key Players & Entities
- Vistagen Therapeutics, Inc. (company) — Registrant
- November 13, 2025 (date) — Date of Report
- Nevada (jurisdiction) — State of Incorporation
- South San Francisco, California (location) — Principal Executive Offices
- 650-577-3600 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Vistagen Therapeutics, Inc.'s Results of Operations and Financial Condition, and to include Financial Statements and Exhibits.
When was this 8-K report filed?
This 8-K report was filed as of November 13, 2025.
In which state is Vistagen Therapeutics, Inc. incorporated?
Vistagen Therapeutics, Inc. is incorporated in Nevada.
What is the address of Vistagen Therapeutics' principal executive offices?
The address of Vistagen Therapeutics' principal executive offices is 343 Allerton Ave., South San Francisco, California 94080.
What is the registrant's telephone number?
The registrant's telephone number, including area code, is (650) 577-3600.
Filing Stats: 545 words · 2 min read · ~2 pages · Grade level 11.6 · Accepted 2025-11-13 16:34:55
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share VTGN Nasdaq Capital Market
Filing Documents
- vtgn-20251113.htm (8-K) — 25KB
- vtgn-20251113xex991.htm (EX-99.1) — 93KB
- image01a.jpg (GRAPHIC) — 5KB
- 0001628280-25-052077.txt ( ) — 248KB
- vtgn-20251113.xsd (EX-101.SCH) — 2KB
- vtgn-20251113_lab.xml (EX-101.LAB) — 21KB
- vtgn-20251113_pre.xml (EX-101.PRE) — 12KB
- vtgn-20251113_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On November 13, 2025, Vistagen Therapeutics, Inc. (the " Company ") issued a press release announcing financial results for its fiscal year 2026 second quarter ended September 30, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. Disclaimer. The information contained in this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Index Exhibit No. Description 99.1 Press Release issued by Vistagen Therapeutics, Inc., dated Nove mber 13 , 2025, furnished herewith 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
Signatures
Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Vistagen Therapeutics, Inc. Date: November 13, 2025 By: /s/ Shawn K. Singh Shawn K. Singh President and Chief Executive Officer